Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

Giovanna Carrà, Antonio Cartellà, Beatrice Maffeo, Alessandro Morotti Department Of Clinical And Biological Sciences, University Of Turin, Orbassano 10043, ItalyCorrespondence: Alessandro MorottiDepartment Of Clinical And Biological Sciences, University Of Turin, Regione Gonzol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carrà G, Cartellà A, Maffeo B, Morotti A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	chronic myeloid leukemia stem cells tyrosine kinase inhibitors Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/d6b035faa8974ec89b243aab7d01bf27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d6b035faa8974ec89b243aab7d01bf27
record_format	dspace
spelling	oai:doaj.org-article:d6b035faa8974ec89b243aab7d01bf272021-12-02T04:43:46ZStrategies For Targeting Chronic Myeloid Leukaemia Stem Cells1179-9889https://doaj.org/article/d6b035faa8974ec89b243aab7d01bf272019-11-01T00:00:00Zhttps://www.dovepress.com/strategies-for-targeting-chronic-myeloid-leukaemia-stem-cells-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Giovanna Carrà, Antonio Cartellà, Beatrice Maffeo, Alessandro Morotti Department Of Clinical And Biological Sciences, University Of Turin, Orbassano 10043, ItalyCorrespondence: Alessandro MorottiDepartment Of Clinical And Biological Sciences, University Of Turin, Regione Gonzole 10, Orbassano 10043, ItalyEmail alessandro.morotti@unito.itAbstract: Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable to target the most immature cellular component of CML, the CML stem cell. This review summarizes new insights into the mechanisms of resistance to TKIs.Keywords: chronic myeloid leukaemia, stem cells, tyrosine kinase inhibitorsCarrà GCartellà AMaffeo BMorotti ADove Medical Pressarticlechronic myeloid leukemiastem cellstyrosine kinase inhibitorsDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 9, Pp 45-52 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic myeloid leukemia stem cells tyrosine kinase inhibitors Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	chronic myeloid leukemia stem cells tyrosine kinase inhibitors Diseases of the blood and blood-forming organs RC633-647.5 Carrà G Cartellà A Maffeo B Morotti A Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
description	Giovanna Carrà, Antonio Cartellà, Beatrice Maffeo, Alessandro Morotti Department Of Clinical And Biological Sciences, University Of Turin, Orbassano 10043, ItalyCorrespondence: Alessandro MorottiDepartment Of Clinical And Biological Sciences, University Of Turin, Regione Gonzole 10, Orbassano 10043, ItalyEmail alessandro.morotti@unito.itAbstract: Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable to target the most immature cellular component of CML, the CML stem cell. This review summarizes new insights into the mechanisms of resistance to TKIs.Keywords: chronic myeloid leukaemia, stem cells, tyrosine kinase inhibitors
format	article
author	Carrà G Cartellà A Maffeo B Morotti A
author_facet	Carrà G Cartellà A Maffeo B Morotti A
author_sort	Carrà G
title	Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_short	Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_full	Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_fullStr	Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_full_unstemmed	Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_sort	strategies for targeting chronic myeloid leukaemia stem cells
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/d6b035faa8974ec89b243aab7d01bf27
work_keys_str_mv	AT carrag strategiesfortargetingchronicmyeloidleukaemiastemcells AT cartellaa strategiesfortargetingchronicmyeloidleukaemiastemcells AT maffeob strategiesfortargetingchronicmyeloidleukaemiastemcells AT morottia strategiesfortargetingchronicmyeloidleukaemiastemcells
_version_	1718401102224818176

Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

Ejemplares similares